Tempo Therapeutics, Inc.

San Diego, CA Doing business as Tempo Therapeutics Inc.

UEI
EA4HW67GFBS1
CAGE
799L6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
3030 Bunker Hill St #308, San Diego, CA 92109, USA
Website
tempothera.com
Founded
2014
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Tempo Therapeutics, Inc.

Tempo Therapeutics, Inc. is a biotechnology and tissue engineering company specializing in speeding up patient recovery. They have received multiple federal grants to support the development of regenerative medicine products, including a synthetic tissue scaffold to treat diabetic wounds and a novel vaccine platform.

Past federal grants awarded to Tempo Therapeutics, Inc. have supported the development and testing of the MAP Wound Matrix, a flowable synthetic tissue scaffold to regenerate tissue over exposed bone for complex wounds in diabetic patients. A $6.5 million project grant from the National Institutes of Health is funding a multi-center clinical trial of the MAP Wound Matrix. The company also received a $1.6 million NIH grant previously to develop the MAP technology for diabetic wounds. Additionally, Tempo Therapeutics has received federal grants from the National Science Foundation, including a $1 million cooperative agreement to develop a multivalent vaccine platform to provide durable immunity against multiple coronaviruses. This builds on an earlier NSF SBIR Phase I grant of $256,000 to develop a vaccine using their technology. The products and technologies Tempo Therapeutics is developing through these federal grants aim to meet significant unmet medical needs and have potential high commercial value.

Quick answers

What is Tempo Therapeutics, Inc.'s UEI?

Tempo Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is EA4HW67GFBS1.

What is Tempo Therapeutics, Inc.'s CAGE code?

Tempo Therapeutics, Inc.'s CAGE code is 799L6.

What is Tempo Therapeutics, Inc.'s primary NAICS code?

Tempo Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Tempo Therapeutics, Inc. located?

Tempo Therapeutics, Inc.'s physical address in SAM.gov is 3030 Bunker Hill St #308, San Diego, CA 92109, USA.

Is Tempo Therapeutics, Inc. registered in SAM.gov?

Yes. Tempo Therapeutics, Inc.'s SAM.gov registration is active through August 26, 2027.

What is Tempo Therapeutics, Inc.'s most recent federal award?

Tempo Therapeutics, Inc.'s most recent federal grant award is Sttr phase II: vaxmap a single dose multivalent vaccine to produce durable and cross-reactive immunity against various… (2308751), from National Science Foundation, on June 15, 2023.

On GovTribe

See Tempo Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors